RET and medullary thyroid gland carcinoma: A selective RET inhibitor, selpercatinib or pralsetinib, can be considered for patients with a positive RET somatic mutation; that is, RET-mutated MTC confirmed by germline testing including tumour mutational burden (TMB) or RET somatic genotyping in patients who are germline wild-type or germline unknown (83).